

PERSONAL INFORMATION

Simone Ferrero



-  Via San Martino 63/8, 16131 Genoa (Italy)
-  3477211628  010511525
-  simoneferrero@me.com
-  www.simoneferrero.com / simone.ferrero@unige.it
-  Skype drferrero

WORK EXPERIENCE

- 01/06/2015–Present **Associate Professor**
Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa (Italy)
- 01/11/2010–31/05/2015 **Assistant Professor**
Academic Unit of Obstetrics and Gynecology, Genoa (Italy)

EDUCATION AND TRAINING

- 10/07/2017 **International Ovarian Tumor Analysis (IOTA) certificate**
Leuven, Belgium
- 16/02/2007 **Doctor of Philosophy (Ph.D.)**
Queen Mary University of London, London (UK)

Research experience: two-dimensional electrophoresis on polyacrylamide gel, immunofixation techniques, liquid chromatography and mass spectrometry, proteomic analysis, ELISA (enzyme-linked immunosorbent assay) and immunocytochemistry.

Thesis: "Protein and cellular studies on peritoneal fluid of women with endometriosis"
- 06/07/2006 **Diplome D'Université de Chirurgie Laparoscopique**
Université Strasbourg 1, Strasbourg (France)
- 06/07/2006 **European University Diploma of Gynaecological Operative Endoscopy**
Clermont-Ferrand University Hospital, l'Université d'Auvergne, Clermont-Ferrand (France)
Thesis: "Laparoscopic treatment of bowel endometriosis"
- 27/10/2004 **Specialist in Gynecology and Obstetrics**
University of Genoa, Genoa (Italy)
Thesis: "Studies on the pathogenesis of endometriosis"
- 01/05/2000 **Habilitation to Medical Profession and inscription**
- 22/07/1999 **Degree in Medicine and Surgery**
University of Genoa, Genoa (Italy)

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C2	C2	C2	C2	C2
French	B2	B2	B1	B1	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

PUBLICATIONS

2003

- Ferrero S**, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a ten-year survey (1990 - 2000). *Acta Obstet Gynecol Scand* 2003;82:229-234.
Impact factor: 1,166
- Ferrero S**, Ragni N. Prognostic value of plasma and serum VEGF levels in patients with resectable hepatocellular carcinoma. *Ann Surg Oncol* 2003;10:1123.
Impact factor: 3,574

2004

- Ferrero S**, Gillott DJ, Anserini P, Remorgida V, Teisner B, Grudzinskas JG. Methodological concerns regarding levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. *Hum Reprod* 2004;19:220-221.
Impact factor: 3,365
- Ferrero S**. Comment on: Matalliotakis IM, Goumenou AG, Koumantakis GE, Neonaki MA, Koumantakis EE, Dionyssopoulou E, Athanassakis I, Vassiliadis S. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines [Int Immunopharmacol 2003; 3(1):81-89]. *Int Immunopharmacol* 2004;4:157-158.
Impact factor: 1,827
- Ferrero S**. Serum levels of mast cell tryptase, vascular endothelial growth factor, and basic fibroblast growth factor in patients with acute pancreatitis. *Pancreas* 2004;28:450.
Impact factor: 1,872
- Ferrero S**. Angiogenic factors in serum of patients with testicular germ cell tumours. *Urol Res* 2004;32:248.
Impact factor: 1,113
- Ferrero S**. Serum and plasma vascular endothelial growth factor levels in testicular cancer patients. *Ann Oncol* 2004;15:989-990.
Impact factor: 4,335
- Ferrero S**, Remorgida V, Ragni N. Preoperative plasma VEGF levels in ovarian masses. *Eur J Gynaecol Oncol* 2004;25:397.
Impact factor: 0,509
- Ferrero S**. Concerns in reporting of serum vascular endothelial growth factor levels: comment on the article by Nakahara et al. *Arthritis Rheum* 2004;50:2037.
Impact factor: 7,414
- Ferrero S**, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2004;115:3-9.
Impact factor: 0,955
- Ferrero S**. Is measurement of serum vascular endothelial growth factor reliable in patients with systemic sclerosis? *J Rheumatol* 2004;31:1468.
Impact factor: 2,860

12. **Ferrero S.** N-octanoylated ghrelin levels in cord and neonatal blood. *J Clin Endocrinol Metab* 2004;89:4768.
Impact factor: 5,778
13. **Ferrero S.** Measurement of circulating vascular endothelial growth factor in obese subjects. *J Am Coll Cardiol* 2004;44:669-670.
Impact factor: 9,133
14. **Ferrero S,** Remorgida V, Ragni N. Comment on "Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies." *Int J Gynecol Cancer* 2004;14:1045.
Impact factor: 1,147
15. **Ferrero S,** Anserini P, Remorgida V, Ragni N. "Triple marker" for ectopic pregnancy. *Fertil Steril* 2004;82:986.
Impact factor: 3,170
16. **Ferrero S.** Active ghrelin levels in women with polycystic ovary syndrome. *Horm Metab Res* 2004;36:654.
Impact factor: 1,946
17. **Ferrero S.** VEGF levels in patients with peripheral arterial occlusive disease receiving LDL-apheresis. *J Clin Apheresis* 2004;19:160.
Impact factor: 1,111
18. Arena E, **Ferrero S.** Pitfalls in the measurement of serum VEGF in children with congenital heart disease. *Ann Thorac Surg* 2004;78:1884-1885.
Impact factor: 2,244
19. **Ferrero S,** Pretta S, Bertoldi S, Anserini P, Remorgida V, Del Sette M, Gandolfo C, Ragni N. Increased frequency of migraine among women with endometriosis. *Hum Reprod* 2004;19:2927-2932.
Impact factor: 3,365
20. **Ferrero S.** Octanoylated and nonoctanoylated ghrelin levels in cord blood. *Clin Endocrinol* 2004;61:649.
Impact factor: 3,023
21. **Ferrero S.** Active ghrelin levels during fetal life and childhood. *J Pediatr* 2004;145:862.
Impact factor: 3,117

2005

22. Remorgida V, Ragni N, **Ferrero S,** Anserini P, Torelli P, Fulcheri E. The involvement of the interstitial Cajal cells and the enteric nervous system in bowel endometriosis. *Hum Reprod* 2005;20:264-271.
Impact factor: 3,669
23. **Ferrero S,** Ragni N. Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer. *Gynecol Oncol* 2005;96:265.
Impact factor: 2,251
24. Arena E, **Ferrero S.** Is measurement of serum vascular endothelial growth factor reliable in patients with active pulmonary tuberculosis? *Chest* 2005;127:686.
Impact factor: 4,008
25. **Ferrero S,** Esposito F, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Quality of sex life in women with endometriosis and deep dyspareunia. *Fertil Steril* 2005;83:573-579.
Impact factor: 3,114
26. **Ferrero S,** Petrera P, Remorgida V, Ragni N. Endometriosis at 2nd surgery-residual or recurrent disease. *Fertil Steril* 2005;83:815.
Impact factor: 3,114
27. **Ferrero S,** Nicoletti A, Ragni N. Measurement of serum vascular endothelial growth factor in breast cancer patients. *Intern Med J* 2005;35:310-311.
Impact factor: 1,518
28. **Ferrero S,** Ragni N, Fulcheri E. Lateral distribution of benign ovarian cysts. *Int J Gynaecol Obstet* 2005;89:150-151.
Impact factor: 1,147
29. **Ferrero S,** Gillott DJ, Anserini P, Remorgida V, Price KM, Ragni N, Grudzinskas JG. Vitamin D binding protein in endometriosis. *J Soc Gynecol Investig* 2005;12:272-277.
Impact factor: 2,887
30. **Ferrero S,** Gillott DJ, Remorgida V, Anserini P, Price K, Ragni N, Grudzinskas JG. Haptoglobin beta chain isoforms in the plasma and peritoneal fluid of women with endometriosis. *Fertil Steril* 2005;83:1536-1543.
Impact factor: 3,114
31. Remorgida V, Ragni N, **Ferrero S,** Anserini P, Torelli P, Fulcheri E. How complete is full thickness disc resection of bowel endometriotic lesions? A prospective surgical and histological study. *Hum Reprod*

- 2005;20:2317-2320.
Impact factor: 3,669
32. **Ferrero S**, Abbamonte LH, Remorgida V, Ragni N. Irritable bowel syndrome and endometriosis. *Eur J Gastroenterol Hepatol* 2005;17:687.
Impact factor: 1,690
33. Ragni N, **Ferrero S**, Prefumo F, Muschiato B, Gorlero F, Gualco M, Fulcheri E. The association between p53 expression, stage and histological features in endometrial cancer. *Eur J Obstet Gynecol Reprod Biol* 2005;123:111-116.
Impact factor: 1,141
34. **Ferrero S**, Anserini P, Remorgida V, Ragni N. Body mass index in endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2005;121:94-98.
Impact factor: 1,141
35. **Ferrero S**, Abbamonte LH, Remorgida V, Ragni N. Abdominal pain, bloating, and urgency. *Obstet Gynecol* 2005;106:195.
Impact factor: 4,170
36. **Ferrero S**, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2005;121:129-138.
Impact factor: 1,141
37. **Ferrero S**, Belluti A, Anserini P, Remorgida V, Ragni N. Is VEGF a marker for ovarian response and pregnancy outcome? *Eur J Obstet Gynecol Reprod Biol* 2005;121:249.
Impact factor: 1,141
38. **Ferrero S**. Is circulating extracellular VEGF increased in preeclamptic women? *Am J Obstet Gynecol* 2005;193:895-896.
Impact factor: 3,083
39. **Ferrero S**, Petrera P, Colombo BM, Navaratnarajah R, Parisi M, Anserini P, Remorgida V, Ragni N. Asthma in women with endometriosis. *Hum Reprod* 2005;20:3514-3517.
Impact factor: 3,669
40. **Ferrero S**, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Future perspectives in the medical treatment of endometriosis. *Obstet Gynecol Surv* 2005;60:817-826.
Impact factor: 3,437

2006

41. **Ferrero S**, Colombo BM. Differences between plasma and serum vascular endothelial growth factor. *Am J Cardiol* 2006;98:424-425.
Impact factor: 3,015
42. **Ferrero S**, Anserini P, Remorgida V, Bentivoglio G, Ragni, N. Total and active ghrelin levels in women with polycystic ovary syndrome. *Hum Reprod* 2006;21:565.
Impact factor: 3,769
43. Alessandri F, Lijoi D, Mistrangelo E, **Ferrero S**, Ragni N. Randomised study of laparoscopic versus mini-laparotomic myomectomy for uterine myomas. *J Minim Invasive Gynecol* 2006;13:92-97.
Impact factor: 0,311
44. **Ferrero S**, Abbamonte LH, Giordano M, Alessandri F, Anserini P, Remorgida V, Ragni N. What is the desired menstrual frequency of women without menstruation-related symptoms? *Contraception* 2006;73:537-541.
Impact factor: 1,882
45. Alessandri F, Mistrangelo E, Lijoi D, **Ferrero S**, Ragni N. A prospective, randomized trial comparing immediate versus delayed catheter removal following hysterectomy. *Acta Obstet Gynecol Scand* 2006;85:716-720.
Impact factor: 1,327
46. **Ferrero S**, Ragni N, Remorgida V. Post-operative digestive symptoms after colorectal resection for endometriosis. *Hum Reprod* 2006;21:1941-1942.
Impact factor: 3,769
47. Capellino S, Montagna P, Villaggio B, Sulli A, Soldano S, **Ferrero S**, Remorgida V, Cutolo M. Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis. *Ann N Y Acad Sci* 2006;1069:263-267.
Impact factor: 1,930
48. **Ferrero S**, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. *Br J Pharmacol* 2006;149:133-135.

- Impact factor: 3,825
 49. **Ferrero S**, Abbamonte LH, Giordano M, Parisi M, Ragni N, Remorgida V. Uterine myomas, dyspareunia, and sexual function. *Fertil Steril* 2006;86:1504-1510.
 Impact factor: 3,277

2007

50. Pretta S, Remorgida V, Abbamonte LH, Anserini P, Ragni N, Del Sette M, Gandolfo C, **Ferrero S**. Atherosclerosis in women with endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2007;132:226-231.
 Impact factor: 1,432
51. Biscaldi E, **Ferrero S**, Fulcheri E, Ragni N, Remorgida V, Rollandi GA. Multislice CT enteroclysis in the diagnosis of bowel endometriosis. *Eur Radiol* 2007;17:211-219.
 Impact factor: 3,405
52. **Ferrero S**, Abbamonte LH, Parisi M, Ragni N, Remorgida V. Dyspareunia and quality of sex life after laparoscopic excision of endometriosis and postoperative administration of triptorelin. *Fertil Steril* 2007;87:227-229.
 Impact factor: 3,168
53. Biscaldi E, **Ferrero S**, Remorgida V, Rollandi GA. Bowel endometriosis: CT-enteroclysis. *Abdom Imaging* 2007;32:441-450.
 Impact factor: 1,213
54. **Ferrero S**, Abbamonte LH, Giordano M, Ragni N, Remorgida V. Deep dyspareunia and sex life after laparoscopic excision of endometriosis. *Hum Reprod* 2007;22:1142-1148.
 Impact factor: 3,543
55. **Ferrero S**, Remorgida V, Ragni N. Prevalence of depression in women with endometriosis. *Acta Obstet Gynecol Scand* 2007;86:111.
 Impact factor: 1,274
56. Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, **Ferrero S**. Letrozole and norethisterone acetate in rectovaginal endometriosis. *Fertil Steril* 2007;88:724-726.
 Impact factor: 3,168
57. Alessandri F, Lijoi D, Mistrangelo E, **Ferrero S**, Ragni N, Remorgida V. Ureteral suspension facilitates surgery for deep pelvic endometriosis. *Fertil Steril* 2007;87:1222-1224.
 Impact factor: 3,168
58. **Ferrero S**. Total and active ghrelin levels in functional hypothalamic amenorrhea. *Fertil Steril* 2007;88:250.
 Impact factor: 3,168
59. Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, **Ferrero S**. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. *Aust N Z J Obstet Gynaecol* 2007;47:222-225.
 Impact factor: 0,833
60. Remorgida V, **Ferrero S**, Fulcheri E, Ragni N, Martin DC. Bowel endometriosis: presentation, diagnosis and treatment. *Obstet Gynecol Surv* 2007;62:461-470.
 Impact factor: 2,395
61. **Ferrero S**, Abbamonte LH, Remorgida V, Anserini P, Ragni N. Images of children born following infertility treatment. *Arch Gynecol Obstet* 2007;275:113-116.
 Impact factor: 0,666
62. Lijoi D, Capua ED, **Ferrero S**, Mistrangelo E, Giannattasio A, Morano S, Ragni N. The efficacy of 2002 CDC guidelines in preventing perinatal group B Streptococcal vertical transmission: a prospective study. *Arch Gynecol Obstet* 2007;275:373-379.
 Impact factor: 0,666
63. **Ferrero S**, Ragni N, Remorgida V, Arena E. CD10 in the cytological diagnosis of endobronchial endometriosis. *Pediatr Pulmonol* 2007;42:746.
 Impact factor: 2,267
64. **Ferrero S**, Gillott DJ, Remorgida V, Anserini P, Leung KY, Ragni N, Grudzinskas JG. Proteomic analysis of peritoneal fluid in women with endometriosis. *J Proteome Res* 2007;6:3402-3411.
 Impact factor: 5,675
65. **Ferrero S**, Remorgida V. Images in clinical medicine. Endometriosis. *N Engl J Med* 2007;357:e8.
 Impact factor: 52,589

2008

66. Montagna P, Capellino S, Villaggio B, Remorgida V, Ragni N, Cutolo M, **Ferrero S**. Peritoneal fluid

macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. *Fertil Steril* 2008;90:156-164.

Impact factor: 4,167

67. Gorlero F, Nicoletti L, Lijoi D, **Ferrero S**, Pullè A, Ragni N. Endometrial directed biopsy during sonohysterography using the NiGo device: prospective study in women with abnormal uterine bleeding. *Fertil Steril* 2008;89:984-990.
Impact factor: 4,167
68. Valenzano Menada M, Remorgida V, Abbamonte LH, Fulcheri E, Ragni N, **Ferrero S**. Transvaginal ultrasonography combined with water-contrast in the rectum in the diagnosis of rectovaginal endometriosis infiltrating the bowel. *Fertil Steril* 2008;89:699-700.
Impact factor: 4,167
69. Valenzano Menada M, Remorgida V, Abbamonte LH, Nicoletti A, Ragni N, **Ferrero S**. Does transvaginal ultrasonography combined with water-contrast in the rectum aid in the diagnosis of rectovaginal endometriosis infiltrating the bowel? *Hum Reprod* 2008;23:1069-1075.
Impact factor: 3,773
70. Mistrangelo E, Febo G, Ferrero B, **Ferrero S**, Deltetto F, Camanni M. Safety and efficacy of vaginal hysterectomy in the large uterus with the LigaSure bipolar diathermy system. *Am J Obstet Gynecol* 2008;199:475.e1-e5.
Impact factor: 3,453
71. **Ferrero S**, Valenzano Menada M, Remorgida V. Reply: diagnosis of rectovaginal endometriosis. *Hum Reprod* 2008;23:2386-2387.
Impact factor: 3,773
72. Valenzano Menada M, Costantini S, Moioli M, Bogliolo S, Papadia A, **Ferrero S**, Dugnani MC. Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. *Breast* 2008;17:631-636.
Impact factor: 2,155
73. **Ferrero S**, Ragni N, Remorgida V. Deep dyspareunia: causes, treatments, and results. *Curr Opin Obstet Gynecol* 2008;20:394-399.
Impact factor: 2,276
74. Casabona F, Bogliolo S, **Ferrero S**, Boccardo F, Campisi C. Axillary reverse mapping in breast cancer: a new microsurgical lymphatic-venous procedure in the prevention of arm lymphedema. *Ann Surg Oncol* 2008;15:3318-3319.
Impact factor: 3,898
75. **Ferrero S**, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. Peritoneal fluid proteome in women with different ASRM stages of endometriosis. *Gynecol Endocrinol* 2008;24:433-441.
Impact factor: 1,359
76. **Ferrero S**, Gillott DJ, Remorgida V, Ragni N, Venturini PL, Grudzinskas JG. Proteomics technologies in endometriosis. *Expert Rev Proteomics* 2008;5:705-714.
Impact factor: 3,848

2009

77. Biscaldi E, **Ferrero S**, Remorgida V, Fulcheri E, Rollandi GA. Rectosigmoid endometriosis with unusual presentation at magnetic resonance imaging. *Fertil Steril* 2009;91:278-280.
Impact factor: 3,970
78. **Ferrero S**, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. Increased expression of one isoform of leucine-rich alpha-2-glycoprotein in peritoneal fluid of women with uterine leiomyomas. *Arch Gynecol Obstet* 2009;279:365-371.
Impact factor: 0,912
79. **Ferrero S**, Anserini P, Abbamonte LH, Ragni N, Camerini G, Remorgida V. Fertility after bowel resection for endometriosis. *Fertil Steril* 2009;92:41-46.
Impact factor: 3,970
80. **Ferrero S**, Camerini G, Ragni N, Remorgida V. Endometriosis and irritable bowel syndrome: co-morbidity or misdiagnosis? *BJOG* 2009;116:129.
Impact factor: 3,437
81. Boccardo F, Casabona F, De Cian F, Friedman D, Villa G, Bogliolo S, **Ferrero S**, Murelli F, Campisi C. Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. *Ann Surg Oncol* 2009;16:703-708.
Impact factor: 4,130

82. Lijoi D, **Ferrero S**, Mistrangelo E, Casa ID, Crosa M, Remorgida V, Alessandri F. Bowel preparation before laparoscopic gynaecological surgery in benign conditions using a 1-week low fibre diet: a surgeon blind, randomized and controlled trial. *Arch Gynecol Obstet* 2009;280:713-718.
Impact factor: 0,912
83. **Ferrero S**, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. Proteomic analysis of peritoneal fluid in fertile and infertile women with endometriosis. *J Reprod Med* 2009;54:32-40.
Impact factor: 0,696
84. **Ferrero S**, Gillott DJ, Remorgida V, Anserini P, Ragni N, Grudzinskas JG. GnRH analogue remarkably down-regulates inflammatory proteins in peritoneal fluid proteome of women with endometriosis. *J Reprod Med* 2009;54:223-231.
Impact factor: 0,696
85. **Ferrero S**, Venturini PL, Ragni N, Camerini G, Remorgida V. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. *Drugs* 2009;69:943-952.
Impact factor: 4,732
86. Casabona F, Bogliolo S, Valenzano Menada M, Sala P, Villa G, **Ferrero S**. Feasibility of axillary reverse mapping during sentinel lymph node biopsy in breast cancer patients. *Ann Surg Oncol* 2009;16:2459-2463.
Impact factor: 4,130
87. **Ferrero S**, Camerini G, Valenzano Menada M, Biscaldi E, Ragni N, Remorgida V. Uterine adenomyosis in persistence of dysmenorrhea after surgical excision of pelvic endometriosis and colorectal resection. *J Reprod Med* 2009;54:366-372.
Impact factor: 0,696
88. **Ferrero S**, Camerini G, Seracchioli R, Ragni N, Venturini PL, Remorgida V. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. *Hum Reprod* 2009;24:3033-3041.
Impact factor: 3,859

2010

89. **Ferrero S**, Bogliolo S, Rossi UG, Baldi C, Valenzano Menada M, Ragni N, Remorgida V. Unusual complication of excision of pelvic endometriosis: pseudoaneurysm of the left uterine artery. *Fertil Steril* 2010;93:264-266.
Impact factor: 3,958
90. Moioli M, Valenzano Menada M, Bentivoglio G, **Ferrero S**. Peripartum cardiomyopathy. *Arch Gynecol Obstet* 2010;281:183-188.
Impact factor: 1,072
91. **Ferrero S**, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. *Hum Reprod* 2010;25:94-100.
Impact factor: 4,357
92. **Ferrero S**, Camerini G, Ragni N, Menada MV, Venturini PL, Remorgida V. Triptorelin improves intestinal symptoms among patients with colorectal endometriosis. *Int J Gynaecol Obstet* 2010;108:250-251.
Impact factor: 1,704
93. Lefebvre RA, **Ferrero S**, Van Colen I, Dhaese I, Camerini G, Fulcheri E, Remorgida V. Influence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis. *Neurogastroenterol Motil* 2010;22:557-63, e121-2.
Impact factor: 3,349
94. **Ferrero S**. Vascular endothelial growth factor concentrations in serum of patients with extensive slow-flow vascular malformations. *Br J Dermatol* 2010;162:1155-1156.
Impact factor: 4,353
95. **Ferrero S**, Camerini G, Ragni N, Venturini PL, Biscaldi E, Seracchioli R, Remorgida V. Letrozole and norethisterone acetate in colorectal endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2010;150:199-202.
Impact factor: 1,764
96. **Ferrero S**, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. *Expert Opin Pharmacother* 2010;11:1123-34.
Impact factor: 2,403
97. **Ferrero S**, Venturini PL, Remorgida V. Letrozole monotherapy in the treatment of uterine myomas. *Fertil Steril* 2010;93:e31.
Impact factor: 3,958
98. **Ferrero S**, Arena E, Morando A, Remorgida V. Prevalence of newly diagnosed endometriosis in women attending the general practitioner. *Int J Gynaecol Obstet* 2010;110:203-7.

- Impact factor: 1,704
99. Alessandri F, Remorgida V, Venturini PL, **Ferrero S**. Unidirectional barbed suture versus continuous suture with intracorporeal knots in laparoscopic myomectomy: a randomized study. *J Minim Invasive Gynecol* 2010;17:725-729.
Impact factor: 1,556
100. **Ferrero S**, Haas S, Remorgida V, Camerini G, Fulcheri E, Ragni N, Straub RH, Capellino S. Loss of sympathetic nerve fibers in intestinal endometriosis. *Fertil Steril* 2010;94:2817-2819.
Impact factor: 3,958
101. Ferraiolo A, Dellacasa I, Bentivoglio G, **Ferrero S**, Ragni N. Evaluation of patients' satisfaction of cervical ripening using dinoprostone by either intravaginal gel or pessary: an open-label, randomized, prospective study. *J Reprod Med* 2010;55:423-429.
Impact factor: 0,883

2011

102. **Ferrero S**, Biscaldi E, Luigi Venturini P, Remorgida V. Aromatase inhibitors in the treatment of bladder endometriosis. *Gynecol Endocrinol* 2011;27:337-40.
Impact factor: 1,581
103. **Ferrero S**, Remorgida V. Endometriosis presenting with hemorrhagic ascites. *Arch Gynecol Obstet* 2011;283:1429-1430.
Impact factor: 1,277
104. **Ferrero S**, Tramalloni D, Venturini PL, Remorgida V. Vaginal danazol for women with rectovaginal endometriosis and pain symptoms persisting after insertion of a levonorgestrel-releasing intrauterine device. *Int J Gynaecol Obstet* 2011;113:116-119.
Impact factor: 2,045
105. **Ferrero S**, Biscaldi E, Morotti M, Venturini PL, Remorgida V, Rollandi GA, Valenzano Menada M. Multidetector computerized tomography enteroclysis vs. rectal water contrast transvaginal ultrasonography in determining the presence and extent of bowel endometriosis. *Ultrasound Obstet Gynecol* 2011;37:603-613.
Impact factor: 3,007
106. Morotti M, Valenzano Menada M, Venturini PL, **Ferrero S**. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. *Expert Opin Drug Metab Toxicol* 2011;7:707-720.
Impact factor: 3,119
107. Biscaldi E, **Ferrero S**, Remorgida V, Rollandi GA. MDCT enteroclysis urography with split-bolus technique provides information on ureteral involvement in patients with suspected bowel endometriosis. *AJR Am J Roentgenol* 2011;196:W635-40.
Impact factor: 2,775
108. **Ferrero S**, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. *Reprod Biol Endocrinol* 2011;9:89.
Impact factor: 2,045
109. **Ferrero S**, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. *Reprod Biol Endocrinol* 2011;9:88.
Impact factor: 2,045
110. Leone Roberti Maggiore U, Soligo M, **Ferrero S**. Should conservative management be considered in women with mixed urinary incontinence prior to surgery? *BJOG* 2011;118:1538
Impact factor: 3,407

2012

111. Morotti M, Podestà S, Musizzano Y, Venturini PL, Bentivoglio G, Fulcheri E, **Ferrero S**. Defective placental adhesion in voluntary termination of second-trimester pregnancy and risk of recurrence in subsequent pregnancies. *J Matern Fetal Neonatal Med* 2012;25:339-42.
Impact factor: 1,495
112. Leone Roberti Maggiore U, **Ferrero S**, Mancuso S, Costantini S. Feasibility and outcome of vaginal paravaginal repair using the Capio suture-capturing device. *Int Urogynecol J* 2012;23:341-347
Impact factor: 2,169
113. Morotti M, Menada MV, Gillott DJ, Venturini PL, **Ferrero S**. The preoperative diagnosis of borderline ovarian tumors: a review of current literature. *Arch Gynecol Obstet* 2012;285:1103-1112.
Impact factor: 1,330

114. Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, **Ferrero S**. Pemetrexed disodium in ovarian cancer treatment. *Expert Opin Investig Drugs* 2012;21:437-449.
Impact factor: 4,744
115. Morotti M, Valenzano Menada M, Venturini PL, **Ferrero S**. Bevacizumab in endometrial cancer treatment. *Expert Opin Biol Ther* 2012;12:649-658.
Impact factor: 3,345
116. Morotti M, Remorgida V, Venturini PL, **Ferrero S**. Endometriosis in menopause: a single institution experience. *Arch Gynecol Obstet* 2012;286:1571-1575.
Impact factor: 1,330
117. Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, Venturini PL, **Ferrero S**. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. *Expert Opin Drug Metab Toxicol* 2012;8:1387-1408.
Impact factor: 2,944
118. **Ferrero S**, Venturini PL, Gillott DJ, Remorgida V, Leone Roberti Maggiore U. Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial. *J Minim Invasive Gynecol* 2012;19:722-730.
Impact factor: 1,608
119. Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, **Ferrero S**. Periurethral injection of polyacrylamide hydrogel for the treatment of stress urinary incontinence: the impact on female sexual function. *J Sex Med* 2012;9:3255-3263.
Impact factor: 3,513

2013

120. Leone Roberti Maggiore U, Alessandri F, Remorgida V, Venturini PL, **Ferrero S**. Vaginal sacrospinous colpopexy using the Capio suture-capturing device versus traditional technique: feasibility and outcome. *Arch Gynecol Obstet* 2013;287:267-274.
Impact factor: 1,279
121. **Ferrero S**, Leone Roberti Maggiore U, Scala C, Di Luca M, Venturini PL, Remorgida V. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. *Arch Gynecol Obstet* 2013;287:447-453.
Impact factor: 1,279
122. Morotti M, **Ferrero S**. Antiangiogenic drugs in the treatment of endometriosis. *Reprod Sci* 2013;20:NP1-2.
Impact factor: 2,179
123. Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, **Ferrero S**. Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. *Arch Gynecol Obstet* 2013;288:131-7.
Impact factor: 1,279
124. Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, **Ferrero S**. Monoclonal antibodies therapies for ovarian cancer. *Expert Opin Biol Ther* 2013;13:739-64.
Impact factor: 3,653
125. Morotti M, Menada MV, Boccardo F, **Ferrero S**, Casabona F, Villa G, Campisi C, Papadia A. Lymphedema microsurgical preventive healing approach for primary prevention of lower limb lymphedema after inguinofemoral lymphadenectomy for vulvar cancer. *Int J Gynecol Cancer* 2013;23:769-774.
Impact factor: 1,949
126. Leone Roberti Maggiore U, **Ferrero S**. Hyperemesis gravidarum: measurement of total and active ghrelin levels. *Arch Gynecol Obstet* 2013;288:719-20.
Impact factor: 1,279
127. Scala C, Leone Roberti Maggiore U, Remorgida V, Venturini PL, **Ferrero S**. Drug safety evaluation of desogestrel. *Expert Opin Drug Saf* 2013;12:433-444.
Impact factor: 2,735
128. Leone Roberti Maggiore U, Venturini PL, **Ferrero S**. Incontinence outcomes in women undergoing primary and repeat midurethral sling procedures. *Obstet Gynecol* 2013;121:1108.
Impact factor: 4,368
129. Leone Roberti Maggiore U, Scala C, Venturini PL, **Ferrero S**. Imidafenacin for the treatment of overactive bladder. *Expert Opin Pharmacother* 2013;14:1383-1397.
Impact factor: 3,085
130. Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, **Ferrero S**. Sorafenib for ovarian cancer. *Expert Opin Investig Drugs* 2013;22:1049-1062.

- Impact factor: 5,432
131. Rosa GM, Bauckneht M, Scala C, Tafi E, Leone Roberti Maggiore U, **Ferrero S**, Brunelli C. Cardiovascular effects of antimuscarinic agents in overactive bladder. *Expert Opin Drug Saf* 2013;12:815-827
Impact factor: 2,735
132. Morotti M, Becker CM, Menada MV, **Ferrero S**. Targeting tyrosine-kinases in ovarian cancer. *Expert Opin Investig Drugs* 2013;22:1265-1279.
Impact factor: 5,432
133. Leone Roberti Maggiore U, Valenzano Menada M, Venturini PL, **Ferrero S**. The potential of sunitinib as a therapy in ovarian cancer. *Expert Opin Investig Drugs* 2013;22:1671-1686.
Impact factor: 5,432
134. Leone Roberti Maggiore U, **Ferrero S**, Salvatore S. Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. *Obstet Gynecol* 2013;122:904-905.
Impact factor: 4,368

2014

135. Leone Roberti Maggiore U, Venturini PL, **Ferrero S**. Operative time required to perform sacrospinous ligament suspension. *Arch Gynecol Obstet* 2014;289:233-234.
Impact factor: 1,364
136. Biscaldi E, **Ferrero S**, Leone Roberti Maggiore U, Remorgida V, Venturini PL, Rollandi GA. Multidetector computerized tomography enema versus magnetic resonance enema in the diagnosis of rectosigmoid endometriosis. *Eur J Radiol* 2014;83:261-267.
Impact factor: 2,369
137. Leone Roberti Maggiore U, Remorgida V, Scala C, Tafi E, Venturini PL, **Ferrero S**. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. *Acta Obstet Gynecol Scand* 2014;93:239-247.
Impact factor: 2,426
138. Rosa GM, **Ferrero S**, Ghione P, Valbusa A, Brunelli C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. *Expert Opin Drug Metab Toxicol* 2014;10:279-291.
Impact factor: 2,831
139. **Ferrero S**, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. *Eur J Obstet Gynecol Reprod Biol* 2014;174:117-122.
Impact factor: 1,695
140. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, **Ferrero S**, Origoni M, Candiani M, Leone Roberti Maggiore U. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. *Climacteric* 2014;17:363-369.
Impact factor: 2,264
141. Gardella B, Porru D, Allegri M, Bogliolo S, Iacobone AD, Minella C, Nappi RE, **Ferrero S**, Spinillo A. Pharmacokinetic considerations for therapies used to treat interstitial cystitis. *Expert Opin Drug Metab Toxicol* 2014;10:673-684.
Impact factor: 2,831
142. Morotti M, Calanni L, Gianola G, Anserini P, Venturini PL, **Ferrero S**. Changes in sexual function after medical or surgical termination of pregnancy. *J Sex Med* 2014;11:1495-1504.
Impact factor: 3,151
143. Leone Roberti Maggiore U, Cardozo L, **Ferrero S**, Sileo F, Cola A, Del Deo F, Torella M, Colacurci N, Candiani M, Salvatore S. Mirabegron in the treatment of overactive bladder. *Expert Opin Pharmacother* 2014;15:873-887.
Impact factor: 3,534
144. **Ferrero S**, Remorgida V, Maganza C, Venturini PL, Salvatore S, Papaleo E, Candiani M, Leone Roberti Maggiore U. Aromatase and endometriosis: estrogens play a role. *Ann N Y Acad Sci* 2014;1317:17-23.
Impact factor: 4,383
145. Leone Roberti Maggiore U1, Scala C, Remorgida V, Venturini PL, Del Deo F, Torella M, Colacurci N, Salvatore S, Ferrari S, Papaleo E, Candiani M, **Ferrero S**. Triptorelin for the treatment of endometriosis. *Expert Opin Pharmacother* 2014;15:1153-1179.
Impact factor: 3,534
146. Morotti M, Remorgida V, Venturini PL, **Ferrero S**. Progestogen-only contraceptive pill compared with

combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. *Eur J Obstet Gynecol Reprod Biol* 2014;179:63-68.

Impact factor: 1,695

147. Bizzarri N, Remorgida V, Leone Roberti Maggiore U, Scala C, Tafi E, Ghirardi V, Salvatore S, Candiani M, Venturini PL, **Ferrero S**. Dienogest in the treatment of endometriosis. *Expert Opin Pharmacother* 2014;15:1889-1902.

Impact factor: 3,534

148. Rosa GM, Bianco D, Parodi A, Valbusa A, Zawaideh C, Bizzarri N, **Ferrero S**, Brunelli C. Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation. *Expert Opin Drug Metab Toxicol* 2014;10:1751-1764.

Impact factor: 2,831

149. Leone Roberti Maggiore U, Scala C, Venturini PL, **Ferrero S**. Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study. *Eur J Obstet Gynecol Reprod Biol* 2014;181:157-162.

Impact factor: 1,695

150. Morotti M, Sozzi F, Remorgida V, Venturini PL, **Ferrero S**. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. *Eur J Obstet Gynecol Reprod Biol* 2014;183:188-192.

Impact factor: 1,695

151. Morotti M, Remorgida V, Venturini PL, **Ferrero S**. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. *Eur J Obstet Gynecol Reprod Biol* 2014;183:178-182.

Impact factor: 1,695

2015

152. Bergamini A, Leone Roberti Maggiore U, **Ferrero S**, Rabaiotti E, Viganò R, Petrone M, De Marzi P, Salvatore S, Candiani M, Mangili G. Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. *Expert Opin Investig Drugs* 2015;24:345-362.

Impact factor: 5,528

153. Bogliolo S, Cassani C, Gardella B, Musacchi V, Babilonti L, Venturini PL, **Ferrero S**, Spinillo A. Current opinion on bevacizumab on endometrial cancer treatment. *Expert Opin Biol Ther* 2015;15:299-307.

Impact factor: 3,743

154. Leone Roberti Maggiore U, **Ferrero S**, Salvatore S. Urinary incontinence and bladder endometriosis: conservative management. *Int Urogynecol J* 2015;26:159-62.

Impact factor: 1,961

155. Leone Roberti Maggiore U, Scala C, Venturini PL, Remorgida V, **Ferrero S**. Endometriotic ovarian cysts do not negatively affect the rate of spontaneous ovulation. *Hum Reprod* 2015;30:299-307.

Impact factor: 4,569

156. Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, **Ferrero S**, Origoni M, Candiani M, Leone Roberti Maggiore. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. *Climateric* 2015;18:219-25

Impact factor: 2,264

157. **Ferrero S**, Leone Roberti Maggiore U. Sunitinib in endometriosis: from bench to bedside. *J Obstet Gynaecol* 2015;35:769

Impact factor: 0,551

158. **Ferrero S**, Scala C, Racca A, Calanni L, Remorgida V, Venturini PL, Leone Roberti Maggiore U. Second surgery for recurrent unilateral endometriomas and impact on ovarian reserve: a case-control study. *Fertil Steril* 2015;103:1236-43

Impact factor: 4,590

159. Leone Roberti Maggiore U, Remorgida V, Sala P, Vellone VG, Biscaldi E, **Ferrero S**. Spontaneous uroperitoneum and preterm delivery in a patient with bladder endometriosis. *J Minim Invasive Gynecol* 2015;22:923-4

Impact factor: 1,575

160. Leone Roberti Maggiore U, **Ferrero S**, Salvatore S, Candiani M. Evaluation of symptoms and methodology of the urodynamic study matter. *J Minim Invasive Gynecol* 2015;22:701-2

Impact factor: 1,575

161. Scala C, Leone Roberti Maggiore U, Candiani M, Venturini PL, **Ferrero S**, Greco T, Cavoretto P. Aberrant right subclavian artery in Down syndrome fetuses: a systematic review and meta-analysis. *Ultrasound*

Obstet Gynecol 2015;46:266-76

Impact factor: 3,853

162. Tafi E, Scala C, Leone Roberti Maggiore U, Bizzarri N, Candiani M, Venturini PL, **Ferrero S**. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. *Expert Opin Drug Saf* 2015;14:965-77
Impact factor: 2,911
163. Ghirardi V, Bizzarri N, Remorgida V, Venturini PL, **Ferrero S**. Intraoperative transrectal ultrasonography for hysteroscopic metroplasty: feasibility and safety. *J Minim Invasive Gynecol* 2015;22:884-8
Impact factor: 1,830
164. Rosa GM, Dorighi U, **Ferrero S**, Brunacci M, Bertero G, Brunelli C. Ranolazine for the treatment of atrial fibrillation. *Expert Opin Investig Drugs* 2015;24:825-36.
Impact factor: 5,528
165. Guadagno A, Grillo F, Vellone VG, **Ferrero S**, Fasoli A, Fiocca R, Mastracci L. Intestinal Endometriosis: Mimicker of Inflammatory Bowel Disease? *Digestion* 2015;92:14-21.
Impact factor: 2,097
166. Bogliolo S, Cassani C, Gardella B, Musacchi V, Babilonti L, Venturini PL, **Ferrero S**, Spinillo A. Oxaliplatin for the treatment of ovarian cancer. *Expert Opin Investig Drugs* 2015;24:1275-86.
Impact factor: 5,528
167. Bizzarri N, Ghirardi V, Remorgida V, Venturini PL, **Ferrero S**. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. *Eur J Obstet Gynecol Reprod Biol* 2015;192:22-6.
Impact factor: 1,695
168. **Ferrero S**, Alessandri F, Racca A, Leone Roberti Maggiore U. Treatment of pain associated with deep endometriosis: alternatives and evidence. *Fertil Steril* 2015;104:771-92.
Impact factor: 4,590
169. Tafi E, Leone Roberti Maggiore U, Alessandri F, Bogliolo S, Gardella B, Vellone VG, Grillo F, Mastracci L, **Ferrero S**. Advances in pharmacotherapy for treating endometriosis. *Expert Opin Pharmacother* 2015;16:2465-83.
Impact factor: 3,543

2016

170. Rosa GM, **Ferrero S**, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular Safety of β 3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. *Eur Urol* 2016;69:311-23.
Impact factor: 16,265
171. Leone Roberti Maggiore U, Silanos R, Carlevaro S, Gratarola A, Venturini PL, **Ferrero S**, Pelosi P. Programmed intermittent epidural bolus versus continuous epidural infusion for pain relief during termination of pregnancy: a prospective, double-blind, randomized trial. *Int J Obstet Anesth* 2016;25:37-44.
Impact factor: 2,085
172. Leone Roberti Maggiore U, **Ferrero S**, Mangili G, Bergamini A, Inversetti A, Giorgione V, Viganò P, Candiani M. A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes. *Hum Reprod Update* 2016;22:70-103.
Impact factor: 11,748
173. Leone Roberti Maggiore U, **Ferrero S**. An overview of early drug development for endometriosis. *Expert Opin Investig Drugs* 2016;25:227-47.
Impact factor: 4,030
174. Carbotti G, Barisione G, Airoidi I, Mezzanzanica D, Bagnoli M, **Ferrero S**, Petretto A, Fabbi M, Ferrini S. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. *Oncotarget* 2015;6:43267-80.
Impact factor: 5,168
175. **Ferrero S**, Racca A, Tafi E, Alessandri F, Venturini PL, Leone Roberti Maggiore U. Ulipristal Acetate Before High Complexity Hysteroscopic Myomectomy: A Retrospective Comparative Study. *J Minim Invasive Gynecol* 2016;23:390-5.
Impact factor: 3,061
176. Bizzarri N, Ghirardi V, Alessandri F, Venturini PL, Valenzano Menada M, Rundle S, Leone Roberti Maggiore U, **Ferrero S**. Bevacizumab for the treatment of cervical cancer. *Expert Opin Biol Ther* 2016;16:407-19.
Impact factor: 3,684
177. Bogliolo S, Cassani C, Dominoni M, Musacchi V, Venturini PL, Spinillo A, **Ferrero S**, Gardella B. Veliparib

for the treatment of ovarian cancer. *Expert Opin Investig Drugs* 2016;25:367-74.

Impact factor: 4,030

178. Bogliolo S, **Ferrero S**, Cassani C, Musacchi V, Zanellini F, Dominoni M, Spinillo A, Gardella B. Single-site Versus Multiport Robotic Hysterectomy in Benign Gynecologic Diseases: A Retrospective Evaluation of Surgical Outcomes and Cost Analysis. *J Minim Invasive Gynecol* 2016;23:603-9.
Impact factor: 3,061
179. Guerriero S, Condous G, van den Bosch T, Valentin L, Leone FP, Van Schoubroeck D, Exacoustos C, Installé AJ, Martins WP, Abrao MS, Hudelist G, Bazot M, Alcazar JL, Gonçalves MO, Pascual MA, Ajossa S, Savelli L, Dunham R, Reid S, Menakaya U, Bourne T, **Ferrero S**, Leon M, Bignardi T, Holland T, Jurkovic D, Benacerraf B, Osuga Y, Somigliana E, Timmerman D. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. *Ultrasound Obstet Gynecol* 2016;48:318-32.
Impact factor: 4,710
180. Bondi C, **Ferrero S**, Scala C, Tafi E, Racca A, Venturini PL, Leone Roberti Maggiore U. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. *Expert Opin Drug Metab Toxicol* 2016;12:1233-46.
Impact factor: 3,027
181. Bergamini A, **Ferrero S**, Leone Roberti Maggiore U, Scala C, Pella F, Vellone VG, Petrone M, Rabaiotti E, Cioffi R, Candiani M, Mangili G. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. *Expert Opin Investig Drugs* 2016;25:1405-1412.
Impact factor: 4,030
182. **Ferrero S**, Alessandri F, Vellone VG, Venturini PL, Leone Roberti Maggiore U. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. *Eur J Obstet Gynecol Reprod Biol* 2016;205:43-7.
Impact factor: 1,666
- 2017**
183. Leone Roberti Maggiore U, Bizzarri N, Scala C, Tafi E, Siesto G, Alessandri F, **Ferrero S**. Symptomatic endometriosis of the posterior cul-de-sac is associated with impaired sleep quality, excessive daytime sleepiness and insomnia: a case-control study. *Eur J Obstet Gynecol Reprod Biol* 2017;209:39-43.
Impact factor: 1,809
184. **Ferrero S**, Biscaldi E, Vellone VG, Venturini PL, Leone Roberti Maggiore U. Computed tomographic colonography versus rectal-water contrast transvaginal ultrasonography in the diagnosis of rectosigmoid endometriosis: a pilot study. *Ultrasound Obstet Gynecol* 2017;49:515-523.
Impact factor: 5,654
185. Leone Roberti Maggiore U, Gupta JK, **Ferrero S**. Treatment of endometrioma for improving fertility. *Eur J Obstet Gynecol Reprod Biol* 2017;209:81-85.
Impact factor: 1,809
186. Leone Roberti Maggiore U, Biscaldi E, Vellone GV, Venturini PL, **Ferrero S**. Magnetic resonance enema versus rectal water contrast transvaginal ultrasonography in the diagnosis of rectosigmoid endometriosis. *Ultrasound Obstet Gynecol* 2017;49:524-532.
Impact factor: 5,654
187. Bogliolo S, Cassani C, Dominoni M, Orlandini A, **Ferrero S**, Iacobone AD, Viazzo F, Venturini PL, Spinillo A, Gardella B. The role of fulvestrant in endometrial cancer. *Expert Opin Drug Metab Toxicol* 2017;13:537-544.
Impact factor: 3,151
188. Leone Roberti Maggiore U, **Ferrero S**, Candiani M, Somigliana E, Viganò P, Vercellini P. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. *Eur Urol* 2017;71:790-807.
Impact factor: 17,581
189. **Ferrero S**. Endometriosis: Modern management of an ancient disease. *Eur J Obstet Gynecol Reprod Biol* 2017;209:1-2.
Impact factor: 1,809
190. Bogani G, Borghi C, Leone Roberti Maggiore U, Ditto A, Signorelli M, Martinelli F, Chiappa V, Lopez C, Sabatucci I, Scaffa C, Indini A, **Ferrero S**, Lorusso D, Raspagliesi F. Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. *J Minim Invasive Gynecol* 2017;24:552-562.

- Impact factor: 3,061
191. Barra F, Lorusso D, Leone Roberti Maggiore U, Ditto A, Bogani G, Raspagliesi F, **Ferrero S**. Investigational drugs for the treatment of cervical cancer. *Expert Opin Investig Drugs* 2017;26:389-402.
Impact factor: 3,883
192. Leone Roberti Maggiore U, Scala C, Tafi E, Racca A, Biscaldi E, Vellone VG, Venturini PL, **Ferrero S**. Spontaneous fertility after expectant or surgical management of rectovaginal endometriosis in women with or without ovarian endometrioma: a retrospective analysis. *Fertil Steril* 2017;107:969-976.
Impact factor: 4,803
193. Morotti M, Venturini PL, Biscaldi E, Racca A, Calanni L, Vellone VG, Stabilini C, **Ferrero S**. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2017;213:4-10.
Impact factor: 1,809
194. **Ferrero S**, Scala C, Tafi E, Racca A, Venturini PL, Leone Roberti Maggiore U. Impact of large ovarian endometriomas on the response to superovulation for in vitro fertilization: A retrospective study. *Eur J Obstet Gynecol Reprod Biol* 2017;213:17-21.
Impact factor: 1,809
195. Scala C, Morlando M, Familiari A, Leone Roberti Maggiore U, **Ferrero S**, D'Antonio F, Khalil A. Fetal Tricuspid Regurgitation in the First Trimester as a Screening Marker for Congenital Heart Defects: Systematic Review and Meta-Analysis. *Fetal Diagn Ther* 2017;42:1-8.
Impact factor: 1,813
196. Leone Roberti Maggiore U, **Ferrero S**, Candiani M, Somigliana E, Viganò P, Vercellini P. Reply to Rodolfo Montironi, Silvia Gasparrini, Antonio Lopez-Beltran, et al's Letter to the Editor re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. *Eur Urol* 2017;71:790-807. Benign Müllerian Lesions in the Urinary Bladder: Endometriosis, Endocervicosis, Endosalpingiosis, and Müllerianosis. *Eur Urol* 2017;72:e142.
Impact factor: 17,581
197. **Ferrero S**, Leone Roberti Maggiore U, Aiello N, Barra F, Ditto A, Bogani G, Raspagliesi F, Lorusso D. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas. *Expert Opin Drug Metab Toxicol* 2017;13:881-889.
Impact factor: 3,151
198. Raspagliesi F, Bogani G, Spinillo A, Ditto A, Bogliolo S, Casarin J, Leone Roberti Maggiore U, Martinelli F, Signorelli M, Gardella B, Chiappa V, Scaffa C, **Ferrero S**, Cromi A, Lorusso D, Ghezzi F. Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience. *Eur J Surg Oncol* 2017;43:2150-2156.
Impact factor: 3,688

2018 *

199. **Ferrero S**, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. *Expert Opin Drug Metab Toxicol* 2018;14:107-116.
Impact factor: 3,151
200. **Ferrero S**, Scala C, Barra F. Regarding "Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy?" *J Minim Invasive Gynecol* 2018;25:541.
Impact factor: 3,061
201. Leone Roberti Maggiore U, **Ferrero S**. To the Editor. *Menopause* 2018;25:357.
Impact factor: 2,673
202. Sikora J, **Ferrero S**, Mielczarek-Palacz A, Kondera-Anasz Z. The delicate balance between the good and the bad IL-1 proinflammatory effects in endometriosis. *Curr Med Chem* 2018;25:2105-2121.
Impact factor: 3,469
203. Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, **Ferrero S**. Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: A prospective open-label comparative study. *Eur J Obstet Gynecol Reprod Biol* 2018;222:89-94.
Impact factor: 1,809
204. Rosa GM, Baccino D, Valbusa A, Scala C, Barra F, Brunelli C, **Ferrero S**. Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. *Expert Opin Drug Saf* 2018;17:487-497.
Impact factor: 3,156

205. Barra F, **Ferrero S**. Epigenetic Drugs in the Treatment of Endometriosis. *Reprod Sci* 2018;1933719118765987.
Impact factor: 2,548
206. Ferro Desideri L, Barra F, **Ferrero S**. Prevention of adverse pulmonary, neurological, and ocular perinatal outcomes by supplementing omega-3 fatty acids during pregnancy. *Am J Obstet Gynecol* 2018;219:120-121.
Impact factor: 5,732
207. Barra F, Scala C, **Ferrero S**. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. *Expert Opin Drug Metab Toxicol* 2018;14:399-415.
Impact factor: 3,151
208. Barra F, **Ferrero S**. The use of retinoic acid for the treatment of endometriosis. *Arch Gynecol Obstet* 2018;298:231-232.
Impact factor: 2,236
209. Barra F, Scala C, Mais V, Guerriero S, **Ferrero S**. Investigational drugs for the treatment of endometriosis, an update on recent developments. *Expert Opin Investig Drugs* 2018;27:445-458.
Impact factor: 3,883
210. Ferro Desideri L, Barra F, Tantari M, **Ferrero S**. To the Editor. *Menopause* 2018;25:950.
Impact factor: 2,673
211. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Fonatella C, Sanfilippo R, Leone Roberti Maggiore U, **Ferrero S**, Lorusso D, Raspagliesi F. Role of bevacizumab in uterine leiomyosarcoma. *Crit Rev Oncol Hematol* 2018;126:45-51.
Impact factor: 4,495
212. Bogani G, Taverna F, Lombardo C, Signorelli M, Chiappa V, Casarin J, Scaffa C, Leone Roberti Maggiore U, Recalcati D, Ditto A, Martinelli F, Borghi C, Perotto S, **Ferrero S**, Lorusso D, Raspagliesi F. Potential impact of introducing a nonavalent HPV vaccination. *Int J Gynaecol Obstet* 2018;142:338-342.
Impact factor: 2,072
213. Baccino D, Ferro Desideri L, Barra F, **Ferrero S**. To the Editor. *Menopause*. 2018;25:1056.
Impact factor: 2,673
214. **Ferrero S**, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. *Drugs* 2018;78:995-1012.
Impact factor: 4,690
215. Ferro Desideri L, Barra F, Scala C, **Ferrero S**. To the Editor. *Menopause*. 2018;25:1165.
Impact factor: 2,673
216. **Ferrero S**, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. *Expert Opin Pharmacother* 2018;19:1109-1125.
Impact factor: 3,475
217. Barra F, Ferro Desideri L, **Ferrero S**. Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis. *Br J Pharmacol* 2018;175:3626-3627.
Impact factor: 6,810
218. Scala C, Leone Roberti Maggiore U, Racca A, Barra F, Vellone VG, Venturini PL, **Ferrero S**. Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. *Ultrasound Obstet Gynecol* (in press; doi: 10.1002/uog.18989)
Impact factor: 5,654
219. **Ferrero S**, Scala C, Stabilini C, Vellone VG, Barra F, Leone Roberti Maggiore U. Transvaginal ultrasonography with or without bowel preparation in the diagnosis of rectosigmoid endometriosis: prospective study. *Ultrasound Obstet Gynecol* (in press; 10.1002/uog.19194)
Impact factor: 5,654
220. Barra F, Scala C, Biscaldi E, Vellone VG, Ceccaroni M, Terrone C, **Ferrero S**. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. *Hum Reprod Update* (in press; 10.1093/humupd/dmy027)
Impact factor: 11,852
221. **Ferrero S**, Barra F, Stabilini C, Vellone VG, Leone Roberti Maggiore U, Scala C. Does bowel preparation improve the performance of rectal water contrast transvaginal ultrasonography in diagnosis of rectosigmoid endometriosis. *J Ultrasound Med* (in press; 10.1002/jum.14790)
Impact factor: 1,530
222. Barra F, Laganà AS, Ghezzi F, Casarinc J, **Ferrero S**. Nintedanib for advanced epithelial ovarian cancer: a change of perspective? Summary of evidence from a systematic review. *Gynecol Obstet Invest* (in press)
Impact factor: 1,183

223. Barra F, Bondi C, Scala C, Vellone VG, **Ferrero S**. Pazopanib for the treatment of gynecological malignancies. *Eur J Gynaecol Oncol* (in press)
Impact factor: 0,617
224. Barra F, Leone Roberti Maggiore U, Bogani G, Ditto A, Signorelli M, Martinelli F, Chiappa V, Lorusso D, Raspagliesi F, **Ferrero S**. New prophylactics Human Papilloma Virus (HPV) vaccines against cervical cancer. *J Obstet Gynaecol* (in press)
Impact factor: 0,545
225. Ferraioli D, Penuela L, Garuti A, Carozzi C, Olivier T, Spina B, Salvi S, **Ferrero S**, Tille J-C, Labidi-Galy SI, Cirmena G, Ballestrero A, Chopin N, Beurrier F, Treilleux I, Ray-Coquard I, Zoppoli G, Vellone VG. Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. *Anal Quant Cytopatho* (in press)
Impact factor: 0,398

2019

226. **Ferrero S**, Vellone VG, Barra F. Pathophysiology of pain in patients with peritoneal endometriosis. *Ann Transl Med*;7(Suppl 1):S8.
Impact factor: 3.689
227. Barra F, Laganà AS, Casarin J, Ghezzi F, Ferro Desideri L, Scala C, **Ferrero S**. Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? *Int J Fertil Steril*;13:89-92.
228. Barra F, Scala C, **Ferrero S**. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. *Drugs Today*;55:237-246.
Impact factor: 1,325
229. Barra F, Romano A, Grandi G, Facchinetti F, **Ferrero S**. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. *Expert Opin Investig Drugs*;28:501-504.
Impact factor: 3,883
230. Leone Roberti Maggiore U, Martinelli F, Dondi G, Bogani G, Chiappa V, Evangelista MT, Liberale V, Ditto A, **Ferrero S**, Raspagliesi F. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. *J Gynecol Oncol*;30:e57.
Impact factor: 4,540
231. Barra F, Ferro Desideri L, **Ferrero S**. Transforming growth factor β (TGF- β): is there a different role with regard to distinct phenotypes of endometriosis? *Immunol Lett*;211:1-2.
Impact factor: 2,436
232. Peñuela LA, Fulcheri E, Vellone VG, Fiocca R, Vigliercio GM, Raiteri R, **Ferrero S**. Atomic force microscopy: a promising aid in diagnosis of uterine smooth muscle neoplasms. *Am J Obstet Gynecol*;221:362-364.
Impact factor: 5,732
233. Bogani G, Serati M, Maggiore UL, Ditto A, Gardella B, **Ferrero S**, Spinillo A, Ghezzi F, Raspagliesi F. Cervical intraepithelial neoplasia in women who had vaccination against HPV. *Int J Gynaecol Obstet*;147:233-237.
Impact factor: 2,072
234. Orecchia P, Balza E, Pietra G, Conte R, Bizzarri N, **Ferrero S**, Mingari MC, Carnemolla B. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. *Cancers* (Basel). 2019;11(9).
235. Barra F, Evangelisti G, **Ferrero S**. Preoperative Hormonal Treatment Before Laparoscopic Approach for Uterine Fibroids: Do We Need It? *J Invest Surg*. Aug 28:1-3.
Impact factor: 1.122
236. Barra F, Seca M, Della Corte L, Giampaolino P, **Ferrero S**. Relugolix for the treatment of uterine fibroids. *Drugs Today (Barc)*;55:503-512.
Impact factor: 1,325
237. Scala C, Leone Roberti Maggiore U, Barra F, Tantari M, **Ferrero S**. Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation. *Medicina (Kaunas)*;55(9).
Impact factor: 1.467
238. Leone Roberti Maggiore U, **Ferrero S**. Methodological concerns on 'Assessment of ovarian reserve after cystectomy versus "one-step" laser vaporization in the treatment of ovarian endometrioma: a small randomized clinical trial'. *Hum Reprod*. Oct 2;34(10):2086-2087.
Impact factor: 4.991

239. **Ferrero S**, Barra F. Proteomic Research of Molecular Defects in Globozoospermia. *Proteomics Clin Appl*;13:e1900111.
Impact factor: 2.324
240. **Ferrero S**, Scala C, Ciccarelli S, Vellone VG, Barra F. Treatment of rectovaginal endometriosis with the etonogestrel-releasing contraceptive implant. *Gynecol Endocrinol*;12:1-5.
241. Pospisilova E, Kiss I, Souckova H, Tomes P, Spicka J, Matkowski R, Jedryka M, **Ferrero S**, Bobek V, Kolostova K. Circulating Endometrial Cells: A New Source of Information on Endometriosis Dynamics. *J Clin Med*. Nov 11;8(11). pii: E1938. doi: 10.3390/jcm8111938.
Impact factor: 5.583
242. La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Tropea A, Tesarik J, Shah M, Kahramanoglu I, Marques Cerentini T, Ponta M, **Ferrero S**. Sexuality in women with endometriosis: a critical narrative review. *Minerva Med*. Nov 11. doi: 10.23736/S0026-4806.19.06299-2.
Impact factor: 2.863
243. Moioli M, Barra F, Maramai M, Valenzano Menada M, Vellone VG, Costantini S, **Ferrero S**. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs. *Expert Opin Investig Drugs*;28:1025-1029.
Impact factor: 3,883
244. Biscaldi E, Barra F, **Ferrero S**. Magnetic Resonance Enema in Rectosigmoid Endometriosis. *Magn Reson Imaging Clin N Am*;28:89-104.
Impact factor: 2.011
245. La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Török P, Shah M, Karaman E, Marques Cerentini T, Di Guardo F, Gullo G, Ponta M, **Ferrero S**. Quality of life in women with endometriosis: a narrative overview. *Minerva Med*. Nov 12. doi: 10.23736/S0026-4806.19.06298-0. [Epub ahead of print]
Impact factor: 2.863
246. Giampaolino P, Della Corte L, Foreste V, Barra F, **Ferrero S**, Bifulco G. Dioxin and endometriosis: a new possible relation based on epigenetic theory. *Gynecol Endocrinol*. Dec 5:1-6. doi: 10.1080/09513590.2019.1698024.
Impact factor: 1,406
247. Evangelisti G, Barra F, Maramai M, Moioli M, Costantini S, **Ferrero S**. Feasibility of Cardiophrenic Lymphadenectomy During Debulking Surgery for Advanced Ovarian Cancer: Early Evidence from Preliminary Data. *J Invest Surg*. 2019 Dec 6:1-2.
Impact factor: 1.122
248. Vitale SG, **Ferrero S**, Ciebiera M, Barra F, Török P, Tesarik J, Vilos GA, Cianci A. Hysteroscopic endometrial resection vs. hysterectomy for abnormal uterine bleeding: impact on quality of life and sexuality. Evidence from a systematic review of randomized controlled trials. *Curr Opin Obstet Gynecol*. Dec 30. doi: 10.1097/GCO.0000000000000609. [Epub ahead of print]
Impact factor: 2,821

2020

249. Barra F, Scala C, Leone Roberti Maggiore U, **Ferrero S**. Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis. *J Clin Med*;9(1).
Impact factor: 5,583
250. **Ferrero S**, Scala C, Vellone VG, Paudice M, Vitale SG, Cianci A, Barra F. Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy. *Gynecol Obstet Invest*. 15:1-6.
Impact factor: 1,183
251. **Ferrero S**, Scala C, Vellone VG, Biscaldi E, Barra F. Transvaginal ultrasound-guided biopsy of adenomyosis. *Ann Transl Med*;7(Suppl 8):S341.
Impact factor: 3.689
252. Ciebiera M, Vitale SG, **Ferrero S**, Vilos GA, Barra F, Caruso S, Laganà AS, Sierant A, Cianci A, Jakiel G. VILAPRISAN, A NEW SELECTIVE PROGESTERONE RECEPTOR MODULATOR IN UTERINE FIBROID PHARMACOTHERAPY - WILL IT REALLY BE A BREAKTHROUGH? *Curr Pharm Des*. 26.
Impact factor: 2,412
253. Barra F, Alessandri F, Evangelisti G, Altieri M, Soriero D, Gustavino C, Centurioni MG, **Ferrero S**. Natural Orifice Transluminal Endoscopic Surgery (NOTES): Landscape of Current Experimental Applications in Gynecological Surgery. *J Invest Surg*. 21:1-2
Impact factor: 1.122

- 254 Della Corte L, Barra F, Foreste V, Giampaolino P, Evangelisti G, **Ferrero S**, Bifulco G. Advances in paclitaxel combinations for treating cervical cancer. *Expert Opin Pharmacother*. 8:1-15.
Impact factor: 3,475

PUBLICATIONS IN MULTICENTRIC STUDIES

2005

1. Hankin C, Thorne C, Newell ML, European Collaborative Study. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? *J Acquir Immune Defic Syndr* 2005;40:364-370.
Impact factor: 3,871

2006

2. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. *AIDS* 2006;20:1419-1427.
Impact factor: 5,632

2007

3. European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. *Clin Infect Dis* 2007;44:1647-1656.
Impact factor: 6,750

2009

4. European Collaborative Study, Patel D, Thorne C, Newell ML, Cortina-Borja M. Levels and patterns of HIV RNA viral load in untreated pregnant women. *Int J Infect Dis* 2009;13:266-273.
Impact factor: 2,167
5. England K, Thorne C, European Collaborative Study. Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe. *Clin Infect Dis* 2009;48:1797-1800.
Impact factor: 8,195

2010

6. European Collaborative Study. Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception. *Antivir Ther* 2010;15:41-49.
Impact factor: 3,774
7. European Collaborative Study, Boer K, England K, Godfried MH, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. *HIV Med* 2010;11:368-378.
Impact factor: 3,575

2011

8. European Collaborative Study in EuroCoord, Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. *Antivir Ther* 2011;16:895-903.
Impact factor: 3,161

2013

9. Bailey H, Townsend CL, Cortina-Borja M, Thorne C; European Collaborative Study in EuroCoord. Improvements in virological control among women conceiving on combination antiretroviral therapy in Western Europe. *AIDS* 2013;27:2312-2315.
Impact factor: 6,407
10. Aebi-Popp K, Mulcahy F, Glass TR, Rudin C, Martinez de Tejada B, Bertisch B, Fehr J, Grawe C, Scheibner K, Rickenbach M, Hoesli I, Thorne C; European Collaborative Study in EuroCoord; Swiss

Mother & Child HIV Cohort Study. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery.
 J Acquir Immune Defic Syndr 2013;64:58-65
 Impact factor: 4,652

EDITORIAL BOARDS

Editorial Board	Annals of Short Reports	2018
Editorial Board	Annals of Gynecology and Obstetrics Research	2018
Editorial Board	Edorium Journal of Gynecology and Obstetrics	2018
Guest Editor for the Endometriosis Special Issue	European Journal of Obstetrics and Gynecology and Reproductive Biology volume 209, 2017 2017 Impact factor: 1,809	from 10-09-2015 to 27-10-2016
Editorial Board	Expert Opinion on Drug Metabolism & Toxicology 2017 Impact factor: 3,151	from 2015
Editorial Board	Gynecology and Pelvic Medicine	2018
Editorial Board	Il Ginecologo, Rivista di Ostetricia e Ginecologia, Kurtis Editore	from 2009 to 2012
Editorial Board	International Journal of Pediatrics and Child Health	2018
Editorial Board	Mini-invasive surgery	2018
Editorial Board	OA Journal of Pregnancy and Child Care	2018
Editorial Board	Journal of Gynecological Oncology	2018
Editorial Board	Journal of Tumor, ACT Publishing Group Limited	from 2014
Editorial Board	Research Journal of Women's Health, Herbert Open Access Journals	from 2014
Editorial Board	World Journal of Gastrointestinal Surgery, Baishideng Publishing Group	2009-2018

BOOKS

- 2008 Cutolo M, **Ferrero S**. Endometriosis. In: Diagnostic criteria in autoimmune diseases. Shoenfeld Y, Cervera R, Gershwin ME Eds. Humana Press, Totowa, Stati Uniti, 2008:271-275.
- 2010 **Ferrero S**, Remorgida V, Venturini PL. Aromatase inhibitors in the treatment of endometriosis. In: Endometriosis: symptoms, diagnosis and treatment. Mitchell LA Ed. Nova Publishers, 2010:213-224.

- 2011 **Ferrero S**, Gillott DJ, Remorgida V, Venturini PL. Proteomics technologies in endometriosis. In: New developments in endometriosis. Matalliotakis A, Arici A Eds. CreateSpace, 2011:180-198.
- 2015 Erasmo I, **Ferrero S**. Management of dysmenorrhea in women with endometriosis. In: Dysmenorrhea: Prevalence, Clinical Characteristics and Management. Welch TM Ed. Nova Publishers, 2015;61-83.
- 2016 Laraud F, **Ferrero S**, Leone Roberti Maggiore U. Mirabegron for the treatment of overactive bladder. Larson E Ed. Nova Publishers, 2016; 157-170.
- 2017 **Ferrero S**, Leone Roberti Maggiore U, Racca A, Remorgida V. Neuropelveology. In: Endometriosis. A concise practical guide to current diagnosis and treatment. Mettler L, Keckstein J, Meinhold-Heerlein I, Alkatout I Eds. EndoPress GmbH, 2017; 332-345.
- 2017 Laraud F, Scala C, **Ferrero S**. Trattamento chirurgico dell'insufficienza cervicale. In: Felis S, Avagliano L Eds. CIC Edizioni Internazionali, 2017:233-240.
- 2018 Editor of the Book "Endometrial cancer: risk factors, management and prognosis." Nova Science Publishers 2018.
- Bondi C, Barra F, **Ferrero S**. Epidemiology and risk factors. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 1-24.
- Vellone GV, Peñuela L, Carbone R, Biatta CM, Spina B, Barra F, **Ferrero S**. Molecular pathology of endometrial carcinoma and its histopathological correlations: beyond a dualistic vision? In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 25-68.
- Peñuela L, Paudice M, Spina B, Barra F, **Ferrero S**, Vellone VG. Histopathological classification. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 69-92.
- Barra F, **Ferrero S**. Clinical presentation and transvaginal ultrasound assessment. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 93-112.
- Biscaldi E, Barra F, Evangelisti G, **Ferrero S**. Radiological assessment. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 113-144.
- Evangelisti G, Barra F, **Ferrero S**. A newer perspective in the surgical approach to endometrial cancer: sentinel lymph node evaluation. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 209-230.
- Daminano G, Barra F, Iaia ML, Bregni G, **Ferrero S**, Mammoliti S. Adjuvant therapy for high-risk endometrial cancer. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 231-250.
- Martelli V, Barra F, **Ferrero S**, Nencioni A. Endometrial cancer in elderly patients. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 289-300.
- Barra F, Evangelisti G, Daminano G, Mammoliti S, **Ferrero S**. New perspectives with targeted drugs. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 301-314.
- Tantari M, Barra F, **Ferrero S**. Conservative treatments for endometrial cancer. In: Endometrial cancer: risk factors, management and prognosis. Ed. Ferrero S. Nova Science Publishers, 2018: 315-320.
- 2018 Coeditor of the Book "Emergenze ed urgenze in Ostetricia e Ginecologica". Eds. Felis S, Frigo MG, D'Alessandro G, Ferrero S. CIC Edizioni Internazionali, 2018.
- 2018 D'Alessandro G, Felis S, **Ferrero S**. Addome acuto in gravidanza. In: Emergenze ed urgenze in Ostetricia e Ginecologica. Eds. Felis S, Frigo MG, D'Alessandro G, Ferrero S. CIC Edizioni Internazionali, 2018: 21-41.
- 2018 Bondi C, Di Domenico S, Barra F, Vellone VG, De Cian F, **Ferrero S**. Sunitinib in ovarian cancer: efficacy and adverse effects. In: Sunitinib: mechanisms, interactions and side effects. Ed. Vasso A. Nova Science

Publishers (in press).

2018 **Ferrero S**, Racca A, Leone Roberti Maggiore U. Endometriosis. In: Female Infertility: Basic Science and Clinical Management. Eds. Mehta J, Woodward B (in press, pagine 55-61).

2018 **Ferrero S**, Leone Roberti Maggiore U, Barra F, Scala C. Modified ultrasonographic techniques. In: How to perform ultrasonography in endometriosis. Eds. Guerriero S, Condous G, Alcazar JL Eds. Springer (in press).

REVIEWER FOR THE FOLLOWING JOURNALS

Acta Obstetrica et Gynecologica Scandinavica
Advances in Therapy
American Journal of Cardiology
Archives of Gynecology and Obstetrics
BMC Cancer
BMJ Case Reports
British Journal of Pharmacology
Case Reports in Obstetrics and Gynecology
Clinical Autonomic Research
Clinical Medicine Insights: Oncology
Drugs
European Journal of Obstetrics & Gynecology and Reproductive Biology
Expert Opinion On Drug Metabolism and Toxicology
Expert Opinion On Drug Safety
Expert Opinion On Investigational Drugs
Expert Review of Endocrinology & Metabolism
Expert Review of Obstetrics & Gynecology
Fertility and Sterility
Gynecological Endocrinology
Gynecologic and Obstetric Investigation
Gynecologic Oncology
Gynecological Surgery
Human Reproduction
International Journal of Clinical Pathology and Diagnosis
International Journal of Fertility & Sterility
International Journal of Gynecology and Obstetrics
International Journal of Women's Health
ISRN Obstetrics and Gynecology
Journal of Obstetrics and Gynaecology
Journal of Gynecology Research
Journal of Pain Research
Journal of Proteome Research
Journal of the American College of Cardiology
Mini-invasive surgery
Molecular Human Reproduction
Nature Clinical Reviews
Nature Reviews Disease Primers
OA Journal of Pregnancy and Child Care
Oman Medical Journal
Proteomics – Clinical Applications
Reproduction, Fertility and Development
Reproductive BioMedicine Online
Sexual & Reproductive Healthcare

The American Journal of Obstetrics and Gynecology
The Journal of Obstetrics and Gynaecology Research
The Medical Letter
Therapeutics and Clinical Risk
Tumor Biology
Ultrasound in Obstetrics and Gynecology
Virchows Archiv